使用免疫抑制剂对黄热病疫苗接种影响的案例分析  

Impact of Immunosuppressant Use on Yellow Fever Vaccine

作　　者：兰雨青 梁少军 LAN Yu-Qing;LIANG Shao-Jun(Guangzhou International Travel Health Care Center(Guangzhou Customs Port Outpatient),Guangzhou 510623)

机构地区：[1]广州国际旅行卫生保健中心(广州海关口岸门诊部),广州510623

出　　处：《中国口岸科学技术》2024年第3期25-30,共6页China Port Science and Technology

摘　　要：黄热病是我国检疫传染病之一,主要在世卫组织非洲区域流行。接种黄热病疫苗是预防黄热病感染,阻止黄热病病毒传播的重要防护措施。由于黄热病疫苗属于减毒活疫苗,免疫抑制人群的接种往往受到限制,可能会造成黄热病疫苗的接种延迟,影响黄热病疫苗的接种率和保护效果。本文针对相关案例讨论免疫抑制剂使用对黄热病疫苗接种的影响,认为应谨慎评估正在使用免疫抑制剂人群接种黄热病疫苗的风险与收益,原则上不推荐接种。Yellow fever is one of the quarantine infectious diseases in China.It is mainly prevalent in the WHO African Region.Yellow fever vaccination is an important measure to prevent the infection and the spread of the virus.As the yellow fever vaccine is a live attenuated vaccine,vaccination of the immunosuppressed population is often restricted,which may result in delayed vaccination of the yellow fever vaccine,affecting the coverage and protection of the yellow fever vaccine.This paper discusses the impact of immunosuppressant use on yellow fever vaccination in relevant cases,and believes that the risks and benefits of yellow fever vaccination in people who are using immunosuppressants should be carefully evaluated,and vaccination is not recommended in principle.

关 键 词：黄热病 黄热病疫苗 免疫抑制剂 免疫接种 禁忌症 

分 类 号：R186[医药卫生—流行病学] R512.8[医药卫生—公共卫生与预防医学]